Patent matrix drives innovation. Bien Bio creates the "Chinese core" of bio-fermentation raw materials.

In the future, Bien Biotech plans to extend its patented technology into the pharmaceutical field. For example, hyaluronic acid derivatives are produced by fermentation technology for joint repair and ophthalmic surgery. Just as the company's CTO said, "Patents are not only technological barriers but also the key to opening up new markets."

Apr 29,2025

In the field of beauty raw materials, technological barriers are at the core of a company's competitiveness. Guangdong Bien Biotechnology Co., Ltd. has gradually broken the monopoly of international raw material giants by building a dual engine of "patent pool + technical standards", and has become an "invisible champion" in the field of biological fermentation technology.

Patent layout: Full coverage of the entire chain from strains to processes
By 2025, Bien Biotech has applied for 12 registered trademarks and 2 invention patents, covering key links such as strain selection and breeding, fermentation processes, and component extraction. Its core patent, "A Method for Fermentation Production of Tremella Fuciformis Polysaccharides" (CN202111457642.0), has increased the extraction efficiency of Tremella fuciformis polysaccharides by 40% by optimizing the medium formula and fermentation conditions, while reducing the impurity content to below 5%. This technology has enabled the company to become the world's first enterprise to achieve industrial fermentation production of tremella fuciformis polysaccharides.

Another patent, "A Preparation Method of Filtrate and Lysate of Bifidobacterium longifolium Fermentation Products" (CN202410984482.2), focuses on the high-value utilization of probiotic metabolic products. By regulating the fermentation temperature and pH value, the company has successfully enriched active ingredients such as small molecule polypeptides and amino acids. The lactic acid content is three times higher than that of French imported products, providing a new raw material option for anti-aging products.

Technical standards: Quality control from raw materials to finished products
Bien Biotech has established a full-chain quality control system from raw material screening to finished product delivery. Its tremella fuciformis polysaccharides need to pass 12 physical and chemical index tests (such as uronic acid content and molecular weight distribution) and 6 safety experiments (such as acute oral toxicity and skin irritation) to ensure compliance with the International Cosmetic Ingredient Specification (INCI). In addition, the company has also participated in the formulation of the group standard "General Technical Requirements for Fermentation Raw Materials for Cosmetics", promoting the standardized development of the industry.

Industry-university-research collaboration: Accelerated Transformation from the laboratory to the market
To accelerate the application of technology, Bien Biotech has established joint laboratories with universities and research institutions. For instance, the "High-throughput Strain Screening Platform" developed in collaboration with Beijing University of Chemical Technology can complete the activity screening of thousands of strains within 72 hours, reducing the research and development cycle by 60%. In addition, the company has also introduced AI simulation technology to predict the metabolic pathways during the fermentation process and reduce the cost of trial and error.

Business value: From technological breakthroughs to market returns
The commercial application of patented technology has brought significant economic benefits to Bien Biotech. Its silver ear polysaccharide raw materials have entered the supply chains of international brands such as Estee Lauder and L 'Oreal, with an annual sales volume exceeding 50 million yuan. The BEN-063 female distiller's grains were used by the domestic emerging brand "HFP" in the whitening essence, and the sales volume exceeded 100,000 bottles in the first month of its launch.

In the future, Bien Biotech plans to extend its patented technology into the pharmaceutical field. For example, hyaluronic acid derivatives are produced by fermentation technology for joint repair and ophthalmic surgery. Just as the company's CTO said, "Patents are not only technological barriers but also the key to opening up new markets."